Combination chemotherapy with or without bevacizumab should be the treatment of choice; cetuximab and panitumumab should be used within the context of their licensed indication Although data for the use of moABs in the treatment of elderly patients are lacking, it is unlikely that they have a different tolerance in the elderly than younger patients Panitumumab prolongs PFS in previously treated mCRC patients but should only be used in patients with wild-type KRAS tumours. Here, KRAS is linked to neoplasm.